vps901 Antibody

What is the biological function of vps901 protein?

Vps901 is a CUE domain-containing protein required for vacuolar protein transport in fission yeast. It functions in the transport pathway of carboxypeptidase Y (CPY) from the Golgi to vacuoles. Research demonstrates that vps901 deletion results in CPY mis-sorting, indicating its essential role in maintaining proper vacuolar trafficking . Additionally, vps901 appears to be involved in membrane trafficking of proteins such as Aat1 from the plasma membrane to the vacuole, but is not required for endosome-to-Golgi transport of proteins like Syb1 .

What structural domains characterize vps901 and which are functionally critical?

Vps901 contains two key functional domains: a VPS9 domain and a CUE domain. The VPS9 domain is evolutionarily conserved and critical for protein function, as demonstrated by complementation studies where budding yeast VPS9 gene expression corrected CPY sorting defects in vps901Δ cells . Within the VPS9 domain, the conserved aspartic acid residue (D296) is essential for activity. Interestingly, while the CUE domain is present, experimental evidence suggests it is not required for CPY sorting function, as vps901-CUE truncation mutants maintained normal CPY processing .

How does vps901 compare with homologous proteins in other organisms?

Vps901 in fission yeast shares functional similarities with Vps9p in budding yeast. Heterologous expression studies showed that S. cerevisiae VPS9 could correct both the CPY sorting defect and vacuolar morphology defects in vps901Δ cells, suggesting conserved functionality across these species . This functional conservation indicates the fundamental importance of VPS9 domain-containing proteins in eukaryotic vacuolar transport mechanisms.

What expression systems are most suitable for generating recombinant vps901 for antibody production?

For vps901 recombinant protein expression, both bacterial and eukaryotic systems can be considered. Based on recent advances in single-chain antibody production technologies, systems like the Sensor-integrated Proteome On Chip (SPOC) platform show promise for expressing proteins directly onto SPR biosensor chips . For vps901 specifically, since it's a yeast protein with potential post-translational modifications, expression in yeast systems (S. cerevisiae or P. pastoris) might preserve native conformations better than bacterial systems, potentially yielding antibodies with higher specificity against native epitopes.

What are the optimal epitope regions within vps901 for antibody development?

When developing antibodies against vps901, researchers should consider targeting unique, accessible regions that distinguish it from vps902 and other related proteins. The VPS9 domain contains conserved regions that might generate cross-reactive antibodies, while unique stretches outside this domain may offer better specificity. Based on mutational studies showing the importance of specific residues like D296, epitopes in functionally critical regions may prove valuable for developing antibodies that can potentially inhibit protein function . Computational epitope prediction combined with structural data should guide peptide design for immunization.

How can I validate the specificity of newly developed vps901 antibodies?

Validation requires a multi-faceted approach. First, perform Western blotting against wild-type and vps901Δ strains to confirm specificity – the antibody should detect a band of appropriate molecular weight only in wild-type samples . Second, conduct immunoprecipitation followed by mass spectrometry to confirm the pulled-down protein is vps901. Third, perform cross-reactivity tests against the homologous vps902 protein to ensure specificity. Finally, use immunofluorescence microscopy to verify that the antibody detects vps901 in expected subcellular locations, such as endosomal structures, and shows absent or altered staining in vps901Δ cells.

How can vps901 antibodies be used to distinguish between different functional states of the protein?

Advanced applications of vps901 antibodies could include developing conformation-specific antibodies that recognize active versus inactive states of the protein. Since the functional importance of the VPS9 domain and specifically the D296 residue has been established, phospho-specific antibodies targeting regulatory modifications could be valuable . Researchers might employ techniques from recent antibody engineering approaches, such as those demonstrated in single-chain antibody variant production, to develop state-specific antibodies . These could be used in combination with mutational studies examining the D296A variant to correlate protein conformation with functional outcomes in vacuolar transport pathways.

What experimental approaches can resolve the differential roles of vps901 and vps902 in cellular trafficking?

To delineate the specific roles of vps901 versus vps902, researchers could employ a combination of genetic and immunological approaches. Specific antibodies against each protein would enable comparative immunoprecipitation studies to identify unique binding partners. Immunofluorescence with dual labeling could reveal distinct localization patterns. Given that vps901Δ cells show defects in CPY transport while vps902Δ cells do not show the same phenotype , researchers could use vps901 antibodies in rescue experiments with chimeric proteins containing domains swapped between vps901 and vps902 to identify the regions responsible for their functional differences.

How can high-throughput mutagenesis approaches be combined with vps901 antibodies to map functional domains?

Researchers can leverage emerging high-throughput antibody screening technologies like the SPOC platform to perform comprehensive mutational analysis of vps901 . Similar to the HER2 VHH paratope mutational scan described in recent literature, researchers could generate hundreds of vps901 point mutants across the VPS9 and CUE domains . By examining how these mutations affect antibody binding, particularly with antibodies targeting functional epitopes, researchers can map critical residues beyond the already-identified D296 . This approach would yield quantitative binding data (ka, kd, KD) for each variant, enabling precise structure-function correlations.

What are the most effective immunoprecipitation protocols for vps901 antibodies in yeast systems?

For immunoprecipitation of vps901 from yeast, researchers should consider the following optimized protocol: (1) Culture cells to mid-log phase and harvest by centrifugation; (2) Lyse cells using glass bead disruption in a buffer containing 50mM Tris-HCl pH 7.5, 150mM NaCl, 0.5% NP-40, with protease inhibitors; (3) Pre-clear lysates with protein A/G beads; (4) Incubate with vps901 antibody (optimally 2-5μg) overnight at 4°C; (5) Capture with protein A/G beads for 2 hours; (6) Wash stringently to remove non-specific interactions; (7) Elute and analyze by SDS-PAGE/Western blotting . For co-immunoprecipitation studies identifying vps901 interaction partners, consider using cross-linking agents like DSP to stabilize transient interactions within the endosomal sorting machinery.

How can I troubleshoot non-specific binding issues with vps901 antibodies in immunofluorescence studies?

Non-specific binding in immunofluorescence can be addressed through several approaches: (1) Optimize fixation methods – for yeast cells, 4% paraformaldehyde for 15 minutes followed by spheroplasting with zymolyase typically gives good results; (2) Increase blocking stringency using 5% BSA with 0.1% saponin for permeabilization; (3) Validate antibody specificity by comparing wild-type and vps901Δ cells – the latter should show no signal; (4) Pre-absorb antibodies with acetone powders prepared from vps901Δ cells to remove cross-reactive antibodies; (5) Use fluorophore-conjugated secondary antibodies with minimal cross-reactivity to yeast proteins; (6) Include appropriate controls, such as no-primary-antibody controls and competitive blocking with immunizing peptide .

What considerations are important when designing proximity ligation assays to study vps901 interactions?

Proximity ligation assays (PLA) offer powerful approaches to visualize protein-protein interactions in situ. When designing PLAs to study vps901 interactions: (1) Select antibody pairs raised in different species (e.g., rabbit anti-vps901 and mouse anti-interactor); (2) Validate each antibody individually by immunofluorescence before attempting PLA; (3) Optimize cell fixation and permeabilization specifically for endosomal structures where vps901 functions; (4) Include appropriate controls – negative controls using vps901Δ cells and positive controls using known interaction partners such as components of the vacuolar sorting machinery; (5) Consider the dynamic nature of protein trafficking interactions, potentially using time-course experiments after synchronizing trafficking events; (6) When quantifying PLA signals, normalize to total protein levels detected by conventional immunofluorescence to account for expression variations .

How can CRISPR-Cas9 genome editing be used effectively with vps901 antibodies to study protein function?

CRISPR-Cas9 technology enables precise genomic modifications that, when combined with specific antibodies, create powerful tools for functional studies. Researchers can generate endogenously tagged vps901 (e.g., with small epitope tags like FLAG or HA) that maintain protein function while enabling detection with high-specificity commercial antibodies. Based on the known CPY transport role of vps901 , researchers could create precise point mutations (e.g., D296A) and assess functional consequences through both phenotypic assays and antibody-based detection of altered interactions or localization. For double knockout studies of vps901 and vps902, CRISPR could generate clean deletions while antibodies verify complete protein absence.

What quantitative proteomic approaches can be combined with vps901 immunoprecipitation to map the temporally dynamic interactome?

To map the dynamic vps901 interactome, researchers should consider multiplexed quantitative proteomics approaches: (1) Perform time-course experiments following stimulation of membrane trafficking pathways; (2) Immunoprecipitate vps901 using validated specific antibodies at different timepoints; (3) Process samples using TMT or iTRAQ labeling for multiplexed mass spectrometry; (4) Analyze data to identify proteins that differentially associate with vps901 across the temporal sequence. This approach could reveal dynamic associations during vesicle formation, transport, and fusion events. Given vps901's role in CPY sorting and Aat1 trafficking , researchers should pay particular attention to cargo adaptor proteins and components of the endosomal sorting machinery that may interact transiently with vps901.

What are the optimal strategies for using vps901 antibodies in super-resolution microscopy to track vesicular trafficking?

For super-resolution imaging of vps901 dynamics: (1) Select antibodies with high specificity and affinity, validated through knockout controls; (2) For live-cell imaging, consider generating nanobody-fluorophore conjugates based on the vps901 antibody, as these smaller molecules provide better resolution; (3) For fixed-cell STORM or PALM microscopy, use directly labeled primary antibodies rather than secondary detection to minimize the linkage error; (4) Design dual-color experiments to simultaneously visualize vps901 and cargo proteins like CPY or Aat1, which would enable tracking of dynamic sorting events ; (5) Employ pulse-chase experimental designs with temporally separated fluorophores to track vesicle maturation; (6) Analyze resulting data with specialized tracking software to quantify vps901-positive vesicle dynamics, including speed, directionality, and fusion/fission events.

How should researchers design experiments to distinguish between direct and indirect effects when using vps901 antibodies in functional studies?

To differentiate direct from indirect effects in vps901 functional studies, implement a multi-faceted experimental design: (1) Combine acute inhibition approaches (using inhibitory antibodies if available) with genetic knockout studies, as acute inhibition is less likely to trigger compensatory mechanisms; (2) Perform rescue experiments with wild-type vps901 and specific domain mutants, especially those affecting the VPS9 domain versus the CUE domain ; (3) Use proximity-dependent labeling methods like BioID or APEX with vps901 antibodies for validation to identify directly interacting proteins; (4) Design time-course experiments to establish the sequence of events following vps901 manipulation; (5) Utilize conditional expression systems to create a temporal profile of cellular responses; (6) Incorporate appropriate controls, including the functionally related vps902 protein, to identify effects specific to vps901 disruption.

What statistical approaches are most appropriate for analyzing immunofluorescence data with vps901 antibodies?

For rigorous statistical analysis of vps901 immunofluorescence data: (1) Collect data from multiple biological replicates (minimum n=3) with technical replicates within each experiment; (2) Perform quantitative image analysis measuring parameters such as signal intensity, colocalization coefficients (with markers of different endosomal compartments), object size, number, and distribution; (3) Test for normal distribution of data using Shapiro-Wilk tests before selecting appropriate statistical tests; (4) For comparing wild-type versus mutant conditions, use t-tests for normally distributed data or non-parametric alternatives like Mann-Whitney for non-normal distributions; (5) For experiments with multiple conditions or timepoints, employ ANOVA with appropriate post-hoc tests, controlling for multiple comparisons; (6) Report effect sizes along with p-values to indicate biological significance; (7) Consider advanced analytical approaches like machine learning for complex pattern recognition in subcellular distribution data .

How can computational modeling integrate with antibody-derived data to predict vps901 function in different cellular contexts?

Integrating computational modeling with experimental antibody data provides powerful insights into vps901 function: (1) Develop protein-protein interaction networks based on immunoprecipitation-mass spectrometry data, identifying hub proteins and functional modules; (2) Create predictive models of vps901 dynamics by incorporating quantitative immunofluorescence data with mathematical models of vesicular transport; (3) Use structural modeling based on the VPS9 domain to predict how mutations like D296A alter protein interactions and function ; (4) Employ systems biology approaches to integrate vps901 data into larger models of endosomal sorting and trafficking pathways; (5) Validate computational predictions using targeted experiments with vps901 antibodies, creating an iterative cycle of model refinement; (6) Develop machine learning algorithms to identify patterns in high-content imaging data that correlate with specific trafficking phenotypes; (7) Use these integrated approaches to predict how vps901 function might differ across cell types or respond to different stressors or pharmacological interventions.